Overview
Description
About
South San Francisco, 94080, CA
United States
Latest press releases
Theravance Biopharma Reaffirmed Financial Guidance Repeatedly Without Disclosing the Material Risk That Its Pivotal Trial Could Fail
NEW YORK, March 18, 2026 /PRNewswire/ -- Theravance Biopharma (NASDAQ: TBPH) shareholders lost approximately 26% when shares collapsed on March 3, 2026. In the quarters leading up to that drop, management reaffirmed financial guidance -- including $75 million in near-term milestone targets -- without quantifying the risk that a negative CYPRESS Phase 3 readout could materially impair the Company's outlook. Shareholders who lost money are encouraged to submit their information here. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
On the Q3 2025 earnings call (November 10, 2025), CEO Rick Winningham stated the Company was "on track to achieve near-term milestones totaling $75 million in the fourth quarter -- $50 million for Trelegy and $25 million for YUPELRI." On the Q2 2025 call (August 12, 2025), CFO Aziz Sawaf reaffirmed "all elements of our 2025 financial guidance." Neither statement addressed the possibility that a CYPRESS failure could trigger an accelerated strategic review, restructuring costs, or a fundamental reassessment of the Company's development-stage spending.
On March 3, 2026, Theravance disclosed that the CYPRESS trial failed to meet its primary endpoint and announced an accelerated strategic review, including termination of the ampreloxetine program. The stock fell approximately 26% in a single session.
Those who purchased TBPH shares and suffered a loss may click here to discuss their legal rights. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
Levi & Korsinsky, LLP | Top 50 Securities Firm | (212) 363-7500 | www.zlk.com
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
View original content to download multimedia:https://www.prnewswire.com/news-releases/tbph-guided-for-75m-in-milestones-while-trial-risk-went-unquantified----levi--korsinsky-llp-302717033.html
SOURCE Levi & Korsinsky, LLP
Theravance Biopharma Told Investors R&D Costs Were Declining Following Completion of CYPRESS Enrollment
NEW YORK, March 11, 2026 /PRNewswire/ -- Theravance Biopharma (NASDAQ: TBPH) shareholders lost approximately 26% of their investment on March 3, 2026, when the Company disclosed that its Phase 3 CYPRESS trial failed. Shareholders who lost money are encouraged to submit their information now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
Theravance reported $22 million in operating expenses while the CYPRESS trial was still enrolling, highlighting substantial cash burn on a single high-risk program. Although the company framed R&D costs as declining post-enrollment, the spending underscores the company's financial dependence on a trial that ultimately failed.
TBPH investors who suffered a loss are encouraged to get more information about this investigation. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
Levi & Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
View original content to download multimedia:https://www.prnewswire.com/news-releases/tbph-reported-22m-in-operating-expenses-while-advancing-trial-enrollment----levi--korsinsky-llp-investigates-302710583.html
SOURCE Levi & Korsinsky, LLP
